PatientID: HIVDR-1778-23

Sebuttemba 27, 2023

Color Code

HR: High-Level Resistance
LR: Low-Level Resistance
IR: Intermediate Resistance

S: Susceptible

| DRUG.CLASS | DRUG | RESISTANCE.PROFILE | DRMS.above.20.percent.prevalence |
|------------|------|--------------------|----------------------------------|
| PI | ATV | S | |
| | DRV | \mathbf{S} | |
| | FPV | \mathbf{S} | |
| | IDV | \mathbf{S} | |
| | LPV | \mathbf{S} | |
| | NFV | \mathbf{S} | |
| | SQV | \mathbf{S} | |
| | TPV | ${f S}$ | |
| NRTI | ABC | ${f S}$ | |
| | AZT | ${f S}$ | |
| | D4T | ${f S}$ | |
| | DDI | ${f S}$ | |
| | FTC | ${f S}$ | |
| | LMV | ${f S}$ | |
| | TDF | \mathbf{S} | |
| NNRTI | DOR | $_{ m HR}$ | |
| | EFV | $_{ m HR}$ | |
| | ETR | IR | G190A |
| | NVP | $_{ m HR}$ | |
| | RPV | $_{ m HR}$ | |
| INSTI | BIC | ${f S}$ | |
| | CAB | ${f S}$ | |
| | DTG | ${f S}$ | |
| | EVG | ${f S}$ | |
| | RAL | ${f S}$ | |

Appendix

Drug abbreviations in full

| DRUG.CLASS | ABBREVIATION | DRUG.NAME |
|------------|--------------|----------------|
| | ATV | Atazanavir |
| | DRV | Darunavir |
| | FPV | Fosamprenavir |
| PI | IDV | Indinavir |
| 11 | LPV | Lopinavir |
| | NFV | Nelfinavir |
| | SQV | Saquinavir |
| | TPV | Tipranavir |
| | ABC | Abacavir |
| | AZT | Azidothymidine |
| | DFT | Stavudine |
| NRTI | DDI | Didanosine |
| | FTC | Emtricitabine |
| | LMV | Lamivudine |
| | TDF | Tenofovir |
| | DOR | Doravirine |
| | EFV | Efavirenz |
| NNRTI | ETR | Etravirine |
| | NVP | Nevirapine |
| | RPV | Rilpivirine |
| | BIC | Bictegravir |
| | CAB | Cabotegravir |
| INSTI | DTG | Dolutegravir |
| | EVG | Elvitegravir |
| | RAL | Raltegravir |

Comments

| DRUG.CLASS | COMMENTS |
|------------|---|
| PI | |
| NRTI | |
| NNRTI | G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It does not significantly reduce susceptibility to RPV, ETR, or DOR. |
| INSTI | |